Contacts: Ann Rosenberg
Deep Knowledge Ventures
Ann.rosenberg@deepknowledgeventures.com

Two Artificial Intelligences unite at a Faberge Museum

Deep Knowledge Ventures salutes its portfolio company, Insilico Medicine on the partnership with IBM Watson and Skolkovo Foundation intended to advance personalized medicine.

Hong Kong, June 23, 2015

On the first day of St. Petersburg International Economic Forum IBM (NYSE:IBM) signed a Memorandum of Understanding with 'Skolkovo' Foundation and the 'First Oncology Research and Advisory Center' (FORAC) - Eastern European R&D Center of Insilico Medicine, on creating first of the kind strategic, technology and go-to-market collaboration that aimed at development of the precision medicine platform in Russia.

The ceremony was held at the historic Faberge Museum at the Shuvalov castle and attended by the senior partner of Deep Knowledge Ventures, two vice presidents of IBM, CEO of Insilico Medicine, CEO of FORAC, management of the Skolkovo Foundation and one of the Russian's richest men, Victor F. Vekselberg.

According to Skolkovo and IBM, the platform will utilize novel clinical decision support solutions to extend healthy productive lives of patients with cancer and other age-related diseases. Within the agreement, IBM and 'First Oncology Research and Advisory Center' will provide the know-how and methods for assisting clinicians in making treatment decisions with support from IBM Watson Health developed by IBM and OncoFinder solution developed by FORAC.

"When it comes to curing cancer and aging, one AI system is good, but two are better. I see this partnership with IBM Watson and OncoFinder as a very important milestone in our portfolio company development. Two systems have a lot to talk about", said Dmitry Kaminskiy, senior partner of Deep Knowledge Ventures.

"IBM Watson is the new standard of excellence in machine-assisted clinical decision making and our scientists and medical doctors working with the combined platform will not only get a chance to treat their patients more effectively, but participate in exciting research resulting in peer-reviewed publications and tangible contributions to extending healthy

productive longevity", said Alex Zhavoronkov, PhD, co-founder of FORAC and CEO of Johns Hopkins University-based Insilico Medicine, Inc..

FORAC is a start-up company within Skolkovo Foundation's Biomed Cluster whose goals are to promote innovation for health and business growth in Russia. On top of its main priority of fighting cancer FORAC intensively collaborates with international partners e.g. Insilico Medicine/USA and Pathway Pharmaceuticals/Hongkong who have an extended focus on drug discovery and drug repurposing.

"The project demonstrates that our Russian startups not only can, but already worthily get high evaluation by the leaders of IT industry. This team can provide unique algorithms, which will save hundreds of oncology patients. I am certain that combining research in medicine and information technologies will lead to fundamental improvement of diagnostics and treatment of patients with various diseases. The collaboration between IBM and FORAC is a great example of Skolkovo innovative ecosystem in action,"- commented Victor Vekselberg, President of Skolkovo Foundation.

Source: Skolkovo/IBM: http://sk.ru/news/b/pressreleases/archive/2015/06/19/ibm-skolkovo-foundation-and-forac-will-jointly-develop-targeted-medicine-platform.aspx

About Deep Knowledge Ventures

Deep Knowledge Ventures is a Hong Kong based investment fund. Focusing on anti-aging technologies, Deep Knowledge Ventures adheres harmonious development of the related fields such as personalized medicine, Artificial Intelligence, Big Data analysis and the intersections of them, which create new industries. That's why our motto is: Investment in disruptive exponential technologies.

For more information, please visit http://www.deepknowledgeventures.com.